文献速递哮喘

支气管热成形术减少气道平滑肌并改善重度哮喘临床应答:TASMA随机试验

Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction and Clinical Response in Severe Asthma. The TASMA Randomized Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

TASMA随机试验将40例重度哮喘患者分为立即BT组与延迟对照组,评估BT对气道平滑肌质量的影响并探索与BT应答相关的患者特征。结果显示立即BT组气道平滑肌质量中位数下降超过50%而对照组无变化,且哮喘控制问卷与生活质量问卷改善均优于对照组;总组治疗应答与血清IgE和嗜酸性粒细胞水平正相关,但与基线气道平滑肌质量无关。

要点

  • BT后气道平滑肌质量中位数下降超过50%,随机对照证实其组织学效应。
  • BT组哮喘控制问卷与生活质量问卷改善均显著优于延迟对照组。
  • 治疗应答与血清IgE和嗜酸性粒细胞正相关,与基线ASM质量无关。

核心结论

  • 与随机非BT对照相比,BT后气道平滑肌质量显著减少。
  • 治疗应答与血清IgE和嗜酸性粒细胞水平相关,但与基线ASM质量无关。

研究设计与样本

  • 随机对照试验,重度哮喘患者40例随机分为立即BT组20例与延迟BT对照组20例。
  • 延迟对照组经6个月标准临床护理后复评并接受BT,两组BT后6个月获取包括活检在内的数据。
  • ASM质量以活检中desmin或α-平滑肌肌动蛋白阳性面积百分比经自动数字分析软件计算。

主要发现

  • 立即BT组(n=17)ASM质量中位数下降超过50%,延迟对照组(n=19)无变化(P=0.0004)。
  • 立即BT组哮喘控制问卷评分改善-0.79(IQR -1.61至0.02),延迟对照组0.09(IQR -0.25至1.17)(P=0.006)。
  • 立即BT组AQLQ评分改善0.83(IQR -0.15至1.69),延迟对照组-0.02(IQR -0.77至0.75)(P=0.04)。
  • 总组(n=35)治疗应答与血清IgE和嗜酸性粒细胞正相关,与基线ASM质量无关联。

临床怎么用

  • BT可显著减少重度哮喘患者气道平滑肌质量并改善哮喘控制与生活质量。
  • 血清IgE和嗜酸性粒细胞水平可能有助于识别BT应答人群,基线ASM质量不宜作为选择依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Bronchial thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass reduction after BT, but appropriate control groups are lacking. Furthermore, as treatment response is variable, identifying optimal candidates for BT treatment is important.Objectives: First, to assess the effect of BT on ASM mass, and second, to identify patient characteristics that correlate with BT response.Methods: Patients with severe asthma (n = 40) were randomized to immediate (n = 20) or delayed (n = 20) BT treatment. Before randomization, clinical, functional, blood, and airway biopsy data were collected. In the delayed control group, reassessment, including biopsies, was performed after 6 months of standard clinical care, followed by BT. In both groups, post-BT data including biopsies were obtained after 6 months. ASM mass (% positive desmin or α-smooth muscle actin area in the total biopsy) was calculated with automated digital analysis software. Associations between baseline characteristics and Asthma Control Questionnaire and Asthma Quality of Life Questionnaire (AQLQ) improvement were explored.Measurements and Main Results: Median ASM mass decreased by >50% in the immediate BT group (n = 17) versus no change in the delayed control group (n = 19) (P = 0.0004). In the immediate group, Asthma Control Questionnaire scores improved with -0.79 (interquartile range [IQR], -1.61 to 0.02) compared with 0.09 (IQR, -0.25 to 1.17) in the delayed group (P = 0.006). AQLQ scores improved with 0.83 (IQR, -0.15 to 1.69) versus -0.02 (IQR, -0.77 to 0.75) (P = 0.04). Treatment response in the total group (n = 35) was positively associated with serum IgE and eosinophils but not with baseline ASM mass.Conclusions: ASM mass significantly decreases after BT when compared with a randomized non-BT-treated control group. Treatment response was associated with serum IgE and eosinophil levels but not with ASM mass.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Goorsenberg AWM, d'Hooghe JNS, Srikanthan K, et al. Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction and Clinical Response in Severe Asthma. The TASMA Randomized Trial. Am J Respir Crit Care Med. 2021. PMID: 32721210. doi:10.1164/rccm.201911-2298OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。